Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Published on November 17, 2023
November 17, 2023 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the agenda, the text of the resolutions and the terms of participation, is online on the Cellectis website at the following address: